AVITA Medical, Inc. (ASX:AVH)

Market Cap	192.51M -52.0%
Revenue (ttm)	107.36M +11.5%
Net Income	-72.84M
EPS	-2.61
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	178,134
Average Volume	396,662
Open	1.290
Previous Close	1.300
Day's Range	1.255 - 1.290
52-Week Range	1.000 - 3.180
Beta	1.81
RSI	48.52
Earnings Date	May 7, 2026

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2020
• Employees: 226
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVH

Financial Performance

In 2025, AVITA Medical's revenue was $71.61 million, an increase of 11.45% compared to the previous year's $64.25 million. Losses were -$48.59 million, -21.44% less than in 2024.

Financial numbers in USD